Crystalline forms of immunomodulators

Abstract

The present invention relates to crystalline forms of 3-substituted 1,2,4-oxadiazole compounds, including anhydrous crystalline forms, their preparation methods, and their related pharmaceutical preparations. The present invention also relates to preparations suitable for pharmaceutical, veterinary, and agricultural uses. [Selected Figure] Figure 6A

Description

[Technical Field]

[0001] Related Applications This application claims the benefit of International Patent Application No. CN2017 / 104,485, filed September 29, 2017, the contents of which are incorporated herein by reference in their entirety. [Background technology]

[0002] The mammalian immune system regulates lymphocyte activation and inactivation through a variety of mechanisms during and after an immune response, including mechanisms that specifically regulate the immune response when and as needed.

[0003] The 3-substituted 1,2,4-oxadiazole compounds function as immunomodulators and can therefore be used to treat cancer, immune disorders, immunodeficiency disorders, inflammatory disorders, infectious diseases, and transplant rejection.

[0004] Given the therapeutic benefits associated with 3-substituted 1,2,4-oxadiazole compounds, there is a need for improved compositions of these compounds. Additionally, there is a need for improved methods for preparing and formulating 3-substituted 1,2,4-oxadiazole compounds. Summary of the Invention [Problem to be solved by the invention]

[0005] One aspect of the present invention relates to an anhydrous crystalline compound having the structure of formula (I): [ka]

[0006] Another aspect of the present invention relates to a process for preparing the anhydrous crystalline compound of formula (I).

[0007] In certain embodiments, the present invention provides pharmaceutical preparations suitable for use in human patients, comprising an anhydrous crystalline compound of Formula (I) and one or more pharmaceutically acceptable excipients. In certain embodiments, the pharmaceutical preparations may be for use in treating or preventing a condition or disease described herein. [Brief explanation of the drawings]

[0008] [Figure 1] FIG. 1 shows the XRPD pattern of Formula (I) Form A. [Figure 2] 1 shows XRPD patterns of anhydrous Form A of Formula (I) from various crystallization conditions. "Form A" represents a common XRPD pattern, which may be produced, for example, by the method of Example 2, Section I. [Figure 3A] FIG. 1 shows crystals formed from a wet cake with the addition of 5 wt % seed crystals and EtOH over 8 hours using polarized light microscopy. [Figure 3B] FIG. 1 shows crystals formed from a dried cake with the addition of 5 wt % seed crystals and EtOH over 8 hours using a polarized light microscope. [Figure 4A] FIG. 1 shows crystals formed from a wet cake with the addition of 5 wt % seed crystals and EtOH over 4 hours using a polarized light microscope. [Figure 4B] FIG. 1 shows crystals formed from a dried cake with the addition of 5 wt % seed crystals and EtOH over 4 hours using a polarized light microscope. [Figure 5A] FIG. 1 shows crystals formed from a wet cake with the addition of 1 wt % seed crystals and EtOH over 4 hours using polarized light microscopy. [Figure 5B] FIG. 1 shows crystals formed from a dried cake with the addition of 1 wt % seed crystals and EtOH over 4 hours using a polarized light microscope. [Figure 6A] FIG. 1 shows crystals formed from a wet cake with the addition of 5 wt % seed crystals and EtOH / H2O over 4 hours using a polarized light microscope. [Figure 6B]FIG. 1 shows crystals formed from a dried cake with the addition of 5 wt % seed crystals and EtOH / H2O over 4 hours using a polarized light microscope. [Figure 7] FIG. 1 shows thermogravimetric analysis and differential scanning calorimetry thermograms of anhydrous Form A. [Figure 8] FIG. 1 shows a comparison of the XRPD patterns of anhydrous Form A of Formula (I) initially, at 60% relative humidity (RH) at 25° C., at 75% RH at 40° C., and after 3 months at 60° C., compared to a reference sample of Form A in solid form. [Figure 9] FIG. 1 shows a comparison of XRPD patterns of anhydrous Form A of Formula (I) in water at 20° C., in water at 30° C., and Form A after solubility testing. [Figure 10] FIG. 1 shows the dynamic vapor sorption isotherm of anhydrous Form A of Formula (I). [Figure 11] FIG. 1 shows a comparison of the XRPD patterns of anhydrous Form A of Formula (I) before and after dynamic vapor sorption. [Figure 12A] FIG. 1 shows the asymmetric unit of a single crystal of anhydrous Form A of Formula (I). [Figure 12B] FIG. 1 shows the proposed proton transfer to form zwitterions in crystals of anhydrous Form A of Formula (I). [Figure 12C] FIG. 1 shows the molecular formula of anhydrous Form A of formula (I) in a single crystal. [Figure 13] FIG. 1 shows a comparison of the XRPD patterns of anhydrous Form A of Formula (I) calculated from the single crystal structure based on a sample. DETAILED DESCRIPTION OF THE INVENTION

[0009] In one embodiment, the present invention provides an anhydrous crystalline compound having the structure of formula (I): [ka]

[0010] In some embodiments, the present invention provides an anhydrous crystalline compound having a structure of formula (I) where all atoms are shown. [ka]

[0011] In certain embodiments, the crystalline compound of Formula (I) is non-solvated (e.g., the crystal lattice does not contain molecules of a solvent). In certain embodiments, the crystalline compound of Formula (I) is anhydrous or substantially anhydrous.

[0012] Any of the crystalline compounds described herein may be used in the manufacture of a medicament for the treatment of any of the diseases or conditions disclosed herein.

[0013] In certain embodiments, the compounds of the present invention may be combined into more than one crystalline form, and these different forms are known herein as "polymorphs."

[0014] In some embodiments, polymorphs of crystalline compounds are characterized by powder X-ray diffraction (XRD). θ represents the diffraction angle measured in degrees. In some embodiments, the diffractometer used in XRD measures the diffraction angle as twice the diffraction angle θ. Thus, in some embodiments, the diffraction patterns described herein refer to X-ray intensity measured versus angle 2θ.

[0015] In certain embodiments, the anhydrous crystalline compound of Formula (I) has 2θ values ​​of 18.8±0.2, 20.5±0.2, 26.4±0.2, 27.5±0.2, and 32.0±0.2. In further embodiments, the anhydrous crystalline compound has 2θ values ​​of 18.8±0.2, 20.5±0.2, 26.1±0.2, 26.4±0.2, 27.5±0.2, 30.6±0.2, and 32.0±0.2. In yet further embodiments, the anhydrous crystalline compound has 2θ values ​​of 15.8±0.2, 16.5±0.2, 18.8±0.2, 20.5±0.2, 25.5±0.2, 26.1±0.2, 26.4±0.2, 27.5±0.2, 30.6±0.2, and 32.0±0.2. In still yet further embodiments, the anhydrous crystalline compound has 2θ values ​​of 15.8±0.2, 16.5±0.2, 18.8±0.2, 20.5±0.2, 21.8±0.2, 22.3±0.2, 24.2±0.2, 25.5±0.2, 26.1±0.2, 26.4±0.2, 27.5±0.2, 30.4±0.2, 30.6±0.2, and 32.0±0.2. In some embodiments, the anhydrous crystalline compound has 2θ values ​​selected from the following peaks listed in Table 1 ±0.2: [Table 1]

[0016] In certain embodiments, the anhydrous crystalline compound of Formula (I) has an XRD pattern designated as Form A substantially as shown in FIG.

[0017] In some embodiments, the anhydrous crystalline compound of Formula (I) exhibits a differential scanning calorimetry (DSC) melt / decomposition with an onset temperature in a range selected from about 197° C. to about 210° C., about 201° C. to about 206° C., and about 202° C. to about 205° C. In certain embodiments, the crystalline compound of Formula (I) is not solvated (e.g., the crystal lattice does not contain molecules of a solvent).

[0018] In certain embodiments, the present invention relates to a pharmaceutical composition comprising an anhydrous crystalline compound of Formula (I) and one or more pharmaceutically acceptable excipients. In certain embodiments, the pharmaceutical composition is selected from a tablet, a capsule, and a suspension.

[0019] As used herein, the term "substantially pure" refers to an anhydrous crystalline polymorph that is greater than 90% pure, meaning that it contains less than 10% of any other compounds, such as alternate polymorphs of the corresponding amorphous compound or crystalline salt. Preferably, the anhydrous crystalline polymorph is greater than 95% pure, or even greater than 98% pure. Method for preparing the anhydrous crystalline form of the compound of formula (I)

[0020] In an embodiment, the present invention relates to a method for preparing an anhydrous crystalline compound having a structure of Formula (I), the method comprising: a) providing a mixture comprising a compound of formula (I) and a solvent; b) crystallizing the compound of formula (I) from a mixture containing the compound of formula (I).

[0021] In certain embodiments, the mixture comprising the compound of Formula (I) and the solvent is a reaction mixture.

[0022] In certain embodiments, the mixture comprising the compound of Formula (I) is a solution. In certain embodiments, the solution comprises the compound of Formula (I) dissolved in a solvent. In some embodiments, the solution comprises a crude solid material comprising the compound of Formula (I) dissolved in a solvent. In some embodiments, the solution comprises a reaction mixture.

[0023] In some embodiments, the mixture is a slurry or suspension. In some embodiments, the slurry or suspension comprises a crude solid material comprising a compound of Formula (I).

[0024] In certain embodiments of the solutions, slurries, and suspensions disclosed herein, the crude solid material comprising the compound of Formula (I) is less than 70% pure, less than 75% pure, less than 80% pure, less than 85% pure, or less than 90% pure with respect to the compound of Formula (I). In certain embodiments, the crude solid material comprising the compound of Formula (I) is less than 90% pure with respect to the compound of Formula (I). In certain embodiments, the crude solid material comprises about 70% to about 90% of the compound of Formula (I). In some embodiments, the purity of the crude solid material is about 70% to about 90% with respect to the compound of Formula (I).

[0025] In some embodiments, after crystallization, the compound of Formula (I) is substantially pure. In some embodiments, the anhydrous crystalline form of the compound of Formula (I) is greater than 90% pure. In some embodiments, the purity of the anhydrous crystalline form of the compound of Formula (I) is selected from greater than 90%, greater than 91%, greater than 92%, greater than 93%, greater than 94%, greater than 95%, greater than 96%, greater than 97%, greater than 98%, and greater than 99%. In some embodiments, the purity of the anhydrous crystalline form of the compound of Formula (I) is greater than 95%. In some embodiments, the purity of the anhydrous crystalline form of the compound of Formula (I) is greater than 98%. In some embodiments, the purity of the anhydrous crystalline form of the compound of Formula (I) is selected from about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, and about 99%.

[0026] In some embodiments, the crystalline compounds produced by the methods of the present invention are anhydrous. In some embodiments, provided herein are methods for preparing an anhydrous crystalline compound having the structure of Formula (I): [ka] The method comprises: a) providing a mixture comprising a compound of formula (I) and a solvent; b) crystallizing the compound of formula (I) from a mixture containing the compound of formula (I).

[0027] In some embodiments, the solvent vapor slowly diffuses into the solid sample.

[0028] In certain embodiments, the mixture comprising the compound of Formula (I) is a solution, and the step of crystallizing the compound from the mixture comprises supersaturating the solution to cause the compound of Formula (I) to precipitate from the solution.

[0029] In some embodiments, supersaturating a mixture containing a compound of Formula (I) involves slowly adding an anti-solvent, such as heptane, hexane, ethanol, or another polar or non-polar liquid that is miscible with the aqueous solution. This allows the solution to cool (with or without seeding), reduce the volume of the solution, or any combination thereof. In some embodiments, the anti-solvent is ethanol. In some embodiments, supersaturating a mixture containing a compound of Formula (I) involves adding an anti-solvent, cooling the solution to below ambient temperature, and reducing the volume of the solution, for example, by evaporating the solvent from the solution. In some embodiments, cooling the solution can be passive (e.g., leaving the solution at ambient temperature) or active (e.g., cooling the solution in an ice bath or freezer).

[0030] In certain embodiments, supersaturating the mixture containing the compound of Formula (I) comprises adding an anti-solvent and maintaining the solution temperature above ambient temperature, e.g., reducing the volume of the solution by evaporating the solvent from the solution. In some embodiments, supersaturating the solution comprises maintaining the solution temperature above ambient temperature. In some embodiments, supersaturating the solution comprises maintaining the solution temperature above about 20°C. In some embodiments, supersaturating the solution comprises maintaining the solution temperature at about 20°C, about 25°C, about 30°C, about 35°C, about 40°C, about 45°C, about 50°C, about 55°C, about 60°C, about 65°C, or about 70°C.

[0031] In certain embodiments, the preparation method further comprises isolating the crystals, for example, by filtering the crystals, by decanting the fluid from the crystals, or by any other suitable separation technique. In further embodiments, the preparation method further comprises washing the crystals.

[0032] In some embodiments, the preparation method further comprises inducing crystallization. The method can also include drying the crystals, for example, under reduced pressure. In some embodiments, inducing precipitation or crystallization comprises secondary nucleation. Nucleation occurs in the presence of seed crystals or interactions with the environment (crystallizer walls, impellers, sonication, etc.).

[0033] In other embodiments, the solvent is acetonitrile, diethyl ether, N,N-dimethylacetamide (DMA), dimethylformamide (DMF), dimethyl sulfoxide (DMSO), dichloromethane, ethanol, ethyl acetate, heptane, hexane, isopropyl acetate, methanol, methyl ethyl ketone, N-methyl-2-pyrrolidone (NMP), tetrahydrofuran, toluene, 2-propanol (isopropanol), 1-butanol, water, or any combination thereof. In some embodiments, the solvent is dichloromethane. In some embodiments, the solvent is tetrahydrofuran.

[0034] In some embodiments, the anti-solvent is selected from tetrahydrofuran, methanol, isopropanol, diethyl ether, ethanol, 1,4-dioxane, acetonitrile, and acetone. In some embodiments, the anti-solvent is added slowly to an aqueous solution containing the compound of Formula (I).

[0035] In some embodiments, the anti-solvent is selected from tetrahydrofuran, methanol, isopropanol, 1,4-dioxane, acetonitrile, and acetone. In some embodiments, the anti-solvent slowly diffuses into the aqueous solution containing the compound of Formula (I).

[0036] In some embodiments, the slurry comprising the compound of Formula (I) and the solvent is mixed prior to isolating the solid. In some embodiments, separation of the solid is performed by filtration or centrifugation.

[0037] In some embodiments, the slurry is maintained at or above ambient temperature. In some embodiments, the slurry is maintained at a temperature greater than about 20° C. In some embodiments, the slurry is maintained at a temperature of about 20° C., about 25° C., about 30° C., about 35° C., about 40° C., about 45° C., about 50° C., about 55° C., about 60° C., about 65° C., or about 70° C.

[0038] In some embodiments, the solvent is a mixture containing water. In some preferred embodiments, the solvent is a mixture containing water and ethanol, isopropanol, methanol, or tetrahydrofuran. In some preferred embodiments, for example, to obtain Form A, the solvent is a mixture containing water and isopropanol, or water and ethanol.

[0039] In some embodiments, the solvent is a mixture comprising EtOH:HO in a volume-to-volume ratio selected from 19:2, 5:1, 2:1, 1:1, and 1:9. In some embodiments, the solvent is a mixture comprising ethanol and water to which additional ethanol or a mixture of ethanol and water has been added. In some embodiments, the mixture comprises a compound of Formula (I) and a 2:1 EtOH:HO (v / v) solvent, and then a 19:2 EtOH:HO mixture is added for crystallization.

[0040]

[0013] In certain embodiments, provided herein is a method for preparing an anhydrous crystalline compound having a structure of Formula (I), the method comprising: a) providing a mixture comprising a compound of formula (I) and a solvent; b) adding an anti-solvent to the mixture; c) crystallizing the compound of formula (I) from a mixture containing the compound of formula (I).

[0041] In some embodiments disclosed herein, the method further comprises adding seed crystals.

[0042] In some embodiments, crystallization is assisted by seeding or seeding, i.e., adding seed crystals to the mixture. In some embodiments, the seed crystals are added at a weight percent of the total mixture selected from about 1 wt%, about 2 wt%, about 3 wt%, about 4 wt%, about 5 wt%, about 6 wt%, about 7 wt%, about 8 wt%, about 9 wt%, and about 10 wt%. In some embodiments, the seed crystals are added at a weight percent of the total mixture selected from about 1 wt%, about 2 wt%, about 3 wt%, about 4 wt%, about 5 wt%, and about 6 wt%. In some embodiments, the seed crystals are added at a weight percent of the total mixture selected from about 3 wt%, about 4 wt%, and about 5 wt%.

[0043] In some embodiments, the seed crystals are Form A seed crystals of Formula (I).

[0044] In some embodiments of the methods disclosed herein, the method further comprises adding an additional anti-solvent.

[0045]

[0013] In certain embodiments, provided herein is a method for preparing an anhydrous crystalline compound having a structure of Formula (I), the method comprising: a) providing a mixture comprising a compound of formula (I) and a solvent; b) adding an anti-solvent to the mixture; c) adding seed crystals to the mixture; d) adding additional anti-solvent to the mixture; e) crystallizing the compound of formula (I) from a mixture containing the compound of formula (I).

[0046] In some embodiments, washing the crystals includes washing with a liquid selected from the group consisting of anti-solvents, acetonitrile, ethanol, heptane, hexane, methanol, tetrahydrofuran, toluene, water, or a combination thereof. As used herein, "anti-solvent" refers to a solvent in which the compound crystals are insoluble, minimally soluble, or partially soluble. In practice, adding an anti-solvent to a solution in which salt crystals are dissolved reduces the solubility of the salt crystals in the solution, thereby promoting precipitation of the salt. In some embodiments, the crystals are washed with a combination of an anti-solvent and an organic solvent. In some embodiments, the anti-solvent is water, and in other embodiments, the anti-solvent is an alkane solvent such as hexane or pentane, or an aromatic hydrocarbon solvent such as benzene, toluene, or xylene. In some embodiments, the anti-solvent is methanol.

[0047] In some embodiments, washing the crystals comprises washing the anhydrous crystalline compound of Formula (I) with a solvent or a mixture of one or more solvents described above. In some embodiments, the solvent or mixture of solvents is cooled before washing.

[0048] In embodiments, the methods for preparing anhydrous crystalline forms of the compound of Formula (I) are used to remove one or more impurities from the compound of Formula (I). In embodiments, the crystallization methods described herein are used to purify the compound of Formula (I), for example, as a final purification step in the preparation of the compound.

[0049] In certain embodiments, the compound of Formula (I) is purified by crystallization. In some embodiments, the purification of the compound of Formula (I) does not involve high performance liquid chromatography (HPLC), such as preparative HPLC. In some embodiments, the purification of the compound of Formula (I) by crystallization is scalable. Advantages of purification by crystallization include, but are not limited to, removal of soluble impurities, ease of the purification process, suitability for large-scale synthesis, acceptable yields, and high product purity.

[0050] In some embodiments, the anhydrous crystalline Form A of Formula (I) is stable throughout the manufacturing process. In some embodiments, the water content and physical properties of the anhydrous crystalline Form A of Formula (I) are not affected by humidity. In some embodiments, the anhydrous crystalline Form A of Formula (I) is not hygroscopic. For example, crystals of the anhydrous crystalline Form A of Formula (I) may retain their crystalline structure and may not change in weight by more than 0.5% even after exposure to an environment of 40°C and 75% humidity for one month.

[0051] In some embodiments, the anhydrous crystalline Form A of Formula (I) was the more stable form. In some embodiments, the anhydrous crystalline Form A of Formula (I) was formed in water or a mixture of ethanol and water. In some embodiments, the temperature was greater than about 10°C, greater than about 15°C, greater than about 20°C, greater than about 25°C, greater than about 30°C, greater than about 35°C, greater than about 40°C, greater than about 45°C, greater than about 50°C, greater than about 55°C, greater than about 60°C, greater than about 65°C, or greater than about 70°C. In some embodiments, the temperature was about 10°C, about 15°C, about 20°C, about 25°C, about 30°C, about 35°C, about 40°C, about 45°C, about 50°C, about 55°C, about 60°C, about 65°C, or about 70°C. In some embodiments, the temperature was about 10°C, about 15°C, about 20°C, about 25°C, or about 30°C. In some embodiments, the temperature was about 20°C.

[0052] In some embodiments, the conversion of Formula (I) to the anhydrous crystalline Form A was complete in about 4 hours, about 8 hours, about 12 hours, about 16 hours, about 20 hours, about 1 day, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, or about 7 days. In some embodiments, the conversion of Formula (I) to the anhydrous crystalline Form A was complete in about 2 hours, about 3 hours, about 4 hours, about 5 hours, about 6 hours, about 7 hours, about 8 hours, about 9 hours, about 10 hours, about 11 hours, about 12 hours, about 13 hours, about 14 hours, about 15 hours, about 16 hours, about 17 hours, about 18 hours, about 19 hours, about 20 hours, about 21 hours, about 22 hours, about 23 hours, about 24 hours, about 25 hours, or about 26 hours. For example, at 20° C., the conversion of Formula (I) to the anhydrous crystalline Form A was complete in about 1 day. Use of the anhydrous crystalline form of the compound of formula (I)

[0053] The compounds of formula (I) are 3-substituted 1,2,4-oxadiazole compounds having the following structure: [ka]

[0054] Functional "exhaustion" (immune dysfunction) in T and B cell subsets is a well-known feature of chronic viral infections, such as those caused by hepatitis B and C viruses and HIV. T cell exhaustion was first described in CD8 T cells from mice chronically infected with lymphocytic choriomeningitis virus clone 13. In the lymphocytic choriomeningitis virus mouse model, repeated antigen stimulation via the T cell antigen receptor promotes the sustained expression of T cell inhibitory receptors, including programmed cell death-1 (PD-1) and lymphocyte-activation gene-3 (LAG-3), on virus-specific CD8 T cells (J. Illingworth et al., J. Immunol. 2013, 190(3):1038-1047).

[0055] Thus, diseases modulated by the immune response, including, but not limited to, cancer, immune disorders, immunodeficiency disorders, inflammatory disorders, infectious diseases, and transplant rejection, can be treated by administering immunomodulatory agents, such as compounds of Formula (I), and compositions disclosed herein. The 3-substituted 1,2,4-oxadiazole compounds function as immunomodulatory agents.

[0056] In certain embodiments, the compounds of Formula (I) modulate an intracellular immune response.

[0057] In other embodiments, the present disclosure provides methods of modulating an immune response in a cell, comprising contacting the cell with a composition comprising the anhydrous crystalline form of the compound of Formula (I) according to any of the above embodiments. In some embodiments, the present disclosure provides methods of modulating an immune response in a cell, comprising contacting the cell with a composition comprising the anhydrous crystalline form of the compound of Formula (I) according to any of the above embodiments.

[0058] In certain embodiments, the present disclosure provides the use of an anhydrous crystalline form of the compound of formula (I) for preparing a medicament for the treatment of, for example, cancer, immune disorders, immunodeficiency disorders, inflammatory disorders, infectious diseases, and transplant rejection.

[0059] According to any of the foregoing embodiments, in some embodiments, contacting with the cells occurs in a subject in need thereof, thereby treating a disease or disorder selected from cancer, an immune disorder, an immunodeficiency disorder, an inflammatory disorder, an infectious disease, and transplant rejection.

[0060] In certain embodiments, the present disclosure provides a method for treating cancer, the method comprising administering to a subject in need thereof a therapeutically effective amount of a composition comprising an anhydrous crystalline form of the compound of Formula (I).

[0061] In certain embodiments, the present disclosure provides methods for inhibiting tumor cell growth and / or metastasis by administering to a subject in need thereof a therapeutically effective amount of a composition comprising an anhydrous crystalline form of the compound of Formula (I).

[0062] Representative tumor cells include, but are not limited to, cells of the following cancers: blastoma (e.g., glioblastoma), breast cancer (e.g., breast adenocarcinoma, primary ductal carcinoma, triple-negative breast cancer, estrogen receptor positive (ER+), progesterone receptor positive (PR+), and / or human epidermal growth factor receptor 2 positive (HER2+)), epithelial cancer (e.g., carcinoma), colon cancer, lung cancer (e.g., small cell lung cancer, non-small cell lung cancer (NSCLC), lung adenocarcinoma, and lung squamous cell carcinoma), melanoma (e.g., cutaneous melanoma, ocular melanoma, cutaneous or intraocular malignant melanoma), and / or cutaneous or intraocular melanoma. melanoma, and lymph node-associated melanoma), prostate cancer (e.g., prostate adenocarcinoma), kidney cancer (e.g., renal cell carcinoma (RCC) and renal carcinoma), bone cancer (e.g., osteosarcoma), pancreatic cancer (e.g., pancreatic adenocarcinoma), skin cancer, head and neck cancer (e.g., head and neck squamous cell carcinoma), uterine cancer, ovarian cancer (e.g., ovarian cancer), colorectal cancer (e.g., microsatellite instability-high colorectal cancer and colorectal adenocarcinoma), rectal cancer, cancer of the anal region, cancer of the peritoneum, stomach cancer (e.g., gastric cancer and gastrointestinal cancer), testicular cancer, cancer of the fallopian tubes, cancer of the endometrium, cervical cancer (e.g., uterine cervical cancer), cancer of the esophagus, small intestine, endocrine system cancer, thyroid cancer, parathyroid cancer, adrenal gland cancer, sarcoma (e.g., soft tissue sarcoma and Kaposi's sarcoma), urethral cancer, penile cancer, chronic or acute leukemia, (e.g., acute myeloid leukemia, chronic myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, hairy cell leukemia, and chronic myeloblastic leukemia), childhood solid tumors, Hodgkin's lymphoma (HL) (e.g., lymphocyte-rich type (LRCHL)), tuberous sclerosis complex (NS) HL), mixed cellularity (MCHL) and lymphocyte depletion (LDHL)), B-cell lymphomas (e.g., diffuse large B-cell lymphoma (DLBCL)), non-Hodgkin's lymphoma (NHL) (e.g., low-grade / follicular non-Hodgkin's lymphoma, small lymphocytic (SL) NHL, intermediate-grade / follicular NHL, intermediate-grade diffuse NHL, high-grade immunoblastic NHL, high-grade lymphoblastic NHL, high-grade small non-cleaved cell NHL, bulky mass NHL, Burkitt's lymphoma, mantle cell lymphoma), AIDS-related lymphoma, cutaneous T-cell lymphoma (e.g.,Mycosis fungoides) and Waldenstrom's macroglobulinemia, post-transplant lymphoproliferative disorder (PTLD), lymphocytic lymphoma, primary CNS lymphoma, and T-cell lymphoma), mesothelioma, thymic carcinoma, myeloma (e.g., multiple myeloma), cancer of the bladder (e.g., bladder adenocarcinoma), ureteral cancer, renal pelvic cancer, liver cancer (e.g., hepatocellular carcinoma, hepatocarcinoma, hepatic carcinoma), pancreatic cancer, post-transplant lymphoproliferative disorder (PTLD), neoplasms of the central nervous system (CNS), tumor angiogenesis, spinal axis tumors, brain stem glioma, pituitary adenoma, epidermoid carcinoma, salivary gland cancer, squamous cell carcinoma, abnormal blood vessel proliferation associated with nevus syndrome, edema (such as that associated with brain tumors), Meig's syndrome, Merkel cell carcinoma, environmentally induced cancers (including those induced by asbestos), and combinations of these cancers.

[0063] In other embodiments, for example, the tumor cells may be cells of a cancer selected from prostate cancer, melanoma, breast cancer, colon cancer, prostate cancer, lung cancer, renal cancer, pancreatic cancer, gastric cancer, bladder cancer, esophageal cancer, mesothelioma, thyroid cancer, thymic cancer, sarcoma, glioblastoma, chronic or acute leukemia, lymphoma, myeloma, Merkel cell carcinoma, epithelial carcinoma, colorectal cancer, vaginal cancer, cervical cancer, ovarian cancer, and head and neck cancer.

[0064] In other embodiments, for example, the tumor cells may be cells of a cancer selected from melanoma, triple-negative breast cancer, non-small cell lung cancer, renal cell carcinoma, pancreatic cancer, gastric cancer, bladder cancer, mesothelioma, Hodgkin's lymphoma, cervical cancer, ovarian cancer, and head and neck squamous cell carcinoma.

[0065] In some embodiments, the tumor cells are cells of a cancer selected from small cell lung cancer, multiple myeloma, bladder cancer, primary ductal carcinoma, ovarian cancer, Hodgkin's lymphoma, gastric cancer, acute myeloid leukemia, and pancreatic cancer.

[0066] In other embodiments, the tumor cells are cells of a cancer selected from endometrial cancer, ovarian cancer, Hodgkin's lymphoma, non-Hodgkin's lymphoma, chronic or acute leukemia (e.g., acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia), lymphocytic lymphoma, and multiple myeloma.

[0067] In some embodiments, the tumor cells are cells of a cancer selected from prostate adenocarcinoma, lung adenocarcinoma, lung squamous cell carcinoma, pancreatic adenocarcinoma, breast cancer, and colorectal adenocarcinoma. In certain embodiments, the tumor cells are derived from breast cancer. In some embodiments, the tumor cells are derived from a breast cancer selected from triple-negative breast cancer, estrogen receptor-positive (ER+), progesterone receptor-positive (PR+), and / or human epidermal growth factor receptor 2 (HER2+). In other embodiments, the tumor cells are from the PAM50+ breast cancer assay panel (Parker, JS et al., J. Clin. Oncol., 2009, 27(8):1160-1167) and are selected from luminal A, luminal B, HER2-excess, basal-like, and normal-like breast cancers.

[0068] In some embodiments, the tumor cells are cells of a cancer selected from triple-negative breast cancer, microsatellite instability-high colorectal cancer, gastric cancer, mesothelioma, pancreatic cancer, and cervical cancer.

[0069] In some embodiments, the tumor cells and / or the subject are immuno-oncology therapy naive. Immuno-oncology uses the subject's immune system to help fight cancer. For example, immuno-oncology therapies include, but are not limited to, atezolizumab (a human monoclonal antibody targeting PD-L1), avelumab (a human monoclonal antibody targeting PD-L1), brentuximab vedotin (an antibody-drug conjugate targeting CD30), durvalamab (a human monoclonal antibody targeting PD-L1), ipilimumab (a human monoclonal antibody targeting CTLA-4), nivolumab (a human monoclonal antibody targeting PD-L1), pembrolizumab (a human monoclonal antibody targeting PD-L1), and pembrolizumab (a human monoclonal antibody targeting PD-L1). These include brolizumab (a human monoclonal antibody targeting PD-L1), tremelimumab (a human monoclonal antibody targeting CTLA-4), CT-011 (an antibody targeting PD-1), MDX-1106 (an antibody targeting PD-1), MK-3475 (an antibody targeting PD-1), YW243.55.S70 (an antibody targeting PD-L1), MPDL3280A (an antibody targeting PD-L1), MDX-1105 (an antibody targeting PD-L1), and MEDI4736 (an antibody targeting PD-L1). In some embodiments, the immuno-oncology agent is selected from an anti-CTLA-4 antibody, an anti-PD-1 antibody, an anti-PD-L1 antibody, an anti-PD-L2 antibody, or an anti-TIGIT antibody (e.g., an antibody disclosed in WO 2015 / 009856).

[0070] In other embodiments, the tumor cells and / or the subject respond to immune checkpoint therapy. In some embodiments, the cancer responds to anti-PD1 therapy. For example, the cancer can include non-small cell lung cancer (NSCLC), melanoma, renal cell carcinoma (RCC), bladder cancer, Hodgkin's lymphoma, and head and neck squamous cell carcinoma.

[0071] Another embodiment of the present disclosure provides a method for treating an infection.

[0072] In yet another embodiment of the present disclosure, there is provided a method for treating an infectious disease, comprising administering to a subject in need thereof a therapeutically effective amount of a composition comprising an anhydrous crystalline form of the compound of formula (I).

[0073] In certain embodiments, the present disclosure provides a use of the anhydrous crystalline form of the compound of formula (I) for preparing a medicament for the treatment of an infectious disease, as well as a method of administering a therapeutically effective amount of a composition comprising the anhydrous crystalline form of the compound of formula (I) for the treatment of an infectious disease.

[0074] In some embodiments, the infectious disease is a bacterial infection, a viral infection, a fungal infection, or a parasitic infection, and the method comprises administering a therapeutically effective amount of a composition comprising an anhydrous crystalline form of the compound of Formula (I) for the treatment of a bacterial infection, a viral infection, a fungal infection, or a parasitic infection.

[0075] In some embodiments, for example, the bacterial infection is anthrax, bacillus, bordetella, borrelia, botulism, brucella, burgholderia, campylobacter, chlamydia, cholera, clostridium, conococcus, corynebacterium, diphtheria, enterobacter, enterococcus, erwinia, escherichia, francisella, haemophilus, heliobacter, cleobacterium, leukemia, leukemia, leukemia virus ... The infection may be caused by at least one bacterium selected from the group consisting of Bucilla, Legionella, Leptospira, leptospirosis, Listeria, Lyme disease, Neisseria meningitidis, Mycobacterium, Mycoplasma, Neisseria, Pasteurella, Pelobacter, Plague, Pneumococcus, Proteus, Pseudomonas, Rickettsia, Salmonella, Serratia, Shigella, Staphylococcus, Streptococcus, Tetanus, Treponema, Vibrio, Yersinia, and Xanthomonas.

[0076] In other embodiments, the viral infection may be caused by at least one virus selected from Adenoviridae, Papillomaviridae, Polyomaviridae, Herpesviridae, Poxviridae, Hepadnaviridae, Parvoviridae, Astroviridae, Caliciviridae, Picornaviridae, Coronoviridae, Flaviviridae, Retroviridae, Togaviridae, Arenaviridae, Bunyaviridae, Filoviridae, Orthomyxoviridae, Paramyxoviridae, Rhabdoviridae, and Reoviridae. In certain embodiments, the virus is selected from the group consisting of arboviral encephalitis virus, adenovirus, herpes simplex type 1, herpes simplex type 2, varicella-zoster virus, Epstein-Barr virus, cytomegalovirus, herpesvirus 8, papillomavirus, BK virus, coronavirus, echovirus, JC virus, smallpox, hepatitis B, bocavirus, parvovirus B19, astrovirus, Norwalk virus, coxsackievirus, hepatitis A, poliovirus, rhinovirus, severe acute respiratory syndrome virus, hepatitis C, yellow fever, dengue virus, West Nile virus, and influenza. The virus may be rash, hepatitis E, human immunodeficiency virus (HIV), human T-cell lymphotropic virus (HTLV), influenza, Guanarito virus, Junin virus, Lassa virus, Machupo virus, Sabia virus, Crimean-Congo hemorrhagic fever virus, Ebola virus, Marburg virus, measles virus, molluscum virus, mumps virus, parainfluenza, respiratory syncytial virus, human metapneumovirus, Hendra virus, Nipah virus, rabies, hepatitis D, rotavirus, orbivirus, coltivirus, vaccinia virus, and bannavirus.

[0077] In other embodiments, for example, the fungal infection may be selected from oral candidiasis, Aspergillus (e.g., fumigatus, niger), Blastomyces dermatitidis, Candida (e.g., albicans, krusei, glabrata, tropicalis), Coccidioides immitis, Cryptococcus (e.g., neoformans), Histoplasma capsulatum, Mucor (Mucor, absidia, rhizobia), Paracoccidioides brasiliensis, sporotrichosis, Sporothrix schenckii, zygomycosis, chromoblastomycosis, lobomycosis, mycetoma, onychomycosis, piedra versicolor, tinea barbae, tinea capitis, tinea corporis, tinea cruris, nicotine, tinea nigricans, tinea pedis, otomycosis, phaeohyphomycosis, and rhinosporidiosis.

[0078] In some embodiments, for example, the parasitic infection is caused by Acanthamoeba, Acanthamoeba, Babesia microti, Balantidium coli, Entamoeba hystolytica, Giardia lamblia, Cryptosporidium muris, Trypanosomatida gambiense, Trypanosomatida rhodesiense, Trypanosoma brucei, Trypanosoma cruzi, Leishmania mexicana, Leishmania braziliensis, Leishmania tropica, Leishmania donovani, or any of the following: donovani, Toxoplasma gondii, Plasmodium vivax, Plasmodium ovale, Plasmodium malariae, Plasmodium falciparum, Pneumocystis carinii, Trichomonas vaginalis, Histomonas meleagridis, Secementea, Trichuris trichiura, Ascaris lumbricoides, Enterobius vermicularis, Ancylostoma duodenale, Naegleria fowleri, Necator americanus, Brazilian hookworm (Nippostrongylus brasiliensis), Strongyloides stercoralis, Wuchereria bancroftiThe infection may be caused by at least one parasite selected from Dracunculus medinensis, Dracunculus medinensis, Schistosoma bancrofti, Dracunculus medinensis ...

[0079] The term "subject" includes mammals (especially humans) and other animals, both domestic (eg, household pets such as cats and dogs) and non-domestic (such as wildlife).

[0080] As used herein, a therapeutic agent that "prevents" a disorder or condition refers to a compound that reduces the occurrence or frequency of a disorder or condition in a statistical sample compared to an untreated control sample, or delays the onset or severity of one or more symptoms of a disorder or condition compared to an untreated control sample.Therefore, preventing cancer includes, for example, reducing the number of detectable cancer-like growths in a group of patients receiving prophylactic treatment compared to an untreated subject group, and / or delaying the appearance of detectable cancer-like growths in a treated group compared to an untreated control group, for example, by a statistically and / or clinically significant amount.Preventing infectious diseases includes, for example, reducing the number of diagnosed infectious diseases in a treated group compared to an untreated control group, and / or delaying the onset of infectious disease symptoms in a treated group compared to an untreated control group.Preventing pain includes, for example, reducing or delaying the degree of pain sensations experienced by subjects in a treated group compared to an untreated control group.

[0081] The term "treating" includes prophylactic and / or therapeutic treatment. The term "prophylactic or therapeutic" treatment is art-recognized and includes administration of one or more of the subject compositions to a host. Treatment is prophylactic (i.e., protects the host from the development of an undesirable condition) when administered prior to the clinical manifestation of an undesirable condition (e.g., a disease or other undesirable condition in a host animal), and therapeutic (i.e., intended to alleviate, ameliorate, or stabilize an existing undesirable condition or its side effects) when administered after the manifestation of an undesirable condition. Pharmaceutical Composition

[0082] In certain embodiments, the present disclosure provides a pharmaceutical composition comprising an anhydrous crystalline form of the compound of formula (I) disclosed herein, optionally mixed with a pharmaceutically acceptable carrier or diluent.

[0083] The present disclosure also provides methods for formulating the disclosed anhydrous crystalline forms of the compound of formula (I) for pharmaceutical administration.

[0084] The compositions and methods of the present disclosure can be used to treat individuals in need thereof. In some embodiments, the individual is a mammal, such as a human, or a non-human mammal. When administered to an animal, such as a human, the composition or compound is preferably administered as a pharmaceutical composition, for example, comprising the anhydrous crystalline form of the compound of Formula (I) of the present disclosure and a pharmaceutically acceptable carrier. Pharmaceutically acceptable carriers are well known in the art and include, for example, aqueous solutions such as water or physiologically buffered saline, or other solvents or vehicles such as glycols, glycerol, oils such as olive oil, or injectable organic esters. In a preferred embodiment, when such pharmaceutical compositions are intended for human administration, particularly invasive administration routes (i.e., routes such as injection or implantation that avoid transport or diffusion through epithelial barriers), the aqueous solutions are pyrogen-free or substantially pyrogen-free. The excipient can be selected, for example, to provide delayed release of the agent or to selectively target one or more cells, tissues, or organs. The pharmaceutical composition may be in unit dosage form such as tablets, capsules (such as sprinkle capsules and gelatin capsules), granules, lyophilized products for reconstitution, powders, liquids, syrups, suppositories, injections, etc. The composition may also be present in a transdermal delivery system, such as a skin patch. The composition may also be present in a solution suitable for topical administration, such as eye drops.

[0085] Pharmaceutically acceptable carriers can include physiologically acceptable agents that stabilize, increase the solubility, or increase the absorption of compounds, such as the anhydrous crystalline form of the compound of Formula (I) of the present disclosure. Examples of such physiologically acceptable agents include carbohydrates such as glucose, sucrose, or dextran, antioxidants such as ascorbic acid or glutathione, chelating agents, low-molecular-weight proteins, or other stabilizers or excipients. The selection of a pharmaceutically acceptable carrier, such as a physiologically acceptable agent, depends, for example, on the route of administration of the composition. The pharmaceutical composition preparation can be a self-emulsifying or self-microemulsifying drug delivery system. The pharmaceutical composition (preparation) can be, for example, a liposome or other polymer matrix into which the anhydrous crystalline form of the compound of Formula (I) of the present disclosure can be incorporated. For example, liposomes containing phospholipids or other lipids are non-toxic, physiologically acceptable, and metabolizable carriers that are relatively easy to prepare and administer.

[0086] The phrase "pharmaceutically acceptable" is used herein to refer to compounds, materials, compositions, and / or dosage forms that are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without undue toxicity, irritation, allergic response, or other problem or complication, and commensurate with a reasonable benefit / risk ratio.

[0087] As used herein, the phrase "pharmaceutically acceptable carrier" refers to a pharmaceutically acceptable material, composition, or vehicle, such as a liquid or solid filler, diluent, excipient, solvent, or encapsulating material. Each carrier must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not harmful to the patient. Some examples of materials that can function as pharmaceutically acceptable carriers include: (1) sugars, such as lactose, glucose, and sucrose; (2) starches, such as corn starch and potato starch; (3) cellulose and its derivatives, such as sodium carboxymethylcellulose, ethylcellulose, and cellulose acetate; (4) powdered tragacanth; (5) malt; (6) gelatin; (7) talc; (8) excipients, such as cocoa butter and suppository wax; (9) peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil, soybean oil, etc. (10) glycols such as propylene glycol, (11) polyols such as glycerin, sorbitol, mannitol, and polyethylene glycol, (12) esters such as ethyl oleate and ethyl laurate, (13) agar, (14) buffers such as magnesium hydroxide and aluminum hydroxide, (15) alginic acid, (16) pyrogen-free water, (17) isotonic saline, (18) Ringer's solution, (19) ethyl alcohol, (20) phosphate buffer, and (21) other non-toxic compatible substances used in pharmaceutical formulations.

[0088] Pharmaceutical compositions (preparations) can be administered to a subject by any of several routes of administration, for example, orally (e.g., as a bolus, such as an aqueous or non-aqueous solution or suspension, tablet, capsule (such as sprinkle capsule and gelatin capsule), bolus, powder, granule, or paste for application to the tongue), absorption through the oral mucosa (e.g., sublingually), anally, rectally, or vaginally (e.g., as a pessary, cream, or foam), parenterally (intramuscularly, intravenously, subcutaneously, or intrathecally, e.g., as a sterile solution or suspension), nasally, intraperitoneally, subcutaneously, transdermally (e.g., as a patch applied to the skin), and topically (e.g., as a cream, ointment, or spray applied to the skin, or as eye drops). The compound may also be formulated for inhalation. In some embodiments, the compound may simply be dissolved or suspended in sterile water. Details of suitable routes of administration and compositions suitable therefor can be found, for example, in U.S. Pat. Nos. 6,110,973, 5,763,493, 5,731,000, 5,541,231, 5,427,798, 5,358,970, and 4,172,896, and the patents cited therein.

[0089] The formulations may be conveniently provided in unit dosage form and may be prepared by any method well known in the art of pharmacy. The amount of active ingredient that can be combined with a carrier material to produce a single dosage form will vary depending on the host being treated and the particular mode of administration. The amount of active ingredient that can be combined with a carrier material to produce a single dosage form will generally be the amount of compound that produces a therapeutic effect. Generally, this amount will range from about 1% to about 99% of the active ingredient, preferably from about 5% to about 70%, and most preferably from about 10% to about 30%, out of 100%.

[0090] Methods of preparing these formulations or compositions include the step of bringing into association an active compound, such as an anhydrous crystalline form of the compound of formula (I) of the present disclosure, with the carrier and, optionally, one or more accessory ingredients. In general, the formulations are prepared by uniformly and intimately bringing into association a compound of the present disclosure with liquid carriers, or finely divided solid carriers, or both, and then, if necessary, shaping the product.

[0091] Formulations of the present disclosure that are suitable for oral administration may be in the form of capsules (such as sprinkle capsules and gelatin capsules), cachets, pills, tablets, lozenges (using a flavored base, usually sucrose and acacia or tragacanth), lyophilizates, powders, granules, or as solutions or suspensions in aqueous or non-aqueous liquids, or as oil-in-water or water-in-oil liquid emulsions, or as elixirs or syrups, or as pastilles (using an inert base, such as gelatin and glycerin or sucrose and acacia), and / or as mouthwashes, etc., each containing a predetermined amount of a compound of the present disclosure as an active ingredient. The composition or compound may also be administered as a bolus, electuary, or paste.

[0092] To prepare solid dosage forms for oral administration (such as capsules (including sprinkle capsules and gelatin capsules), tablets, pills, dragees, powders, granules, etc.), the active ingredient is mixed with one or more pharmaceutically acceptable carriers, such as sodium citrate or dicalcium phosphate, and / or any of the following: (1) fillers or extenders, such as starch, lactose, sucrose, glucose, mannitol, and / or silicic acid; (2) binders, such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidone, sucrose, and / or acacia; (3) humectants, such as glycerol; (4) sorbents, such as sorbitol, ... (4) disintegrating agents such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate; (5) solution retarders such as paraffin; (6) absorption accelerators such as quaternary ammonium compounds; (7) wetting agents such as cetyl alcohol and glycerol monostearate; (8) absorbents such as kaolin and bentonite clay; (9) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycol, and sodium lauryl sulfate, and mixtures thereof; (10) complexing agents such as modified and unmodified cyclodextrins; and (11) coloring agents. For capsules (such as sprinkle capsules and gelatin capsules), tablets, and pills, pharmaceutical compositions may also contain buffering agents. Solid compositions of a similar type may also be used as fillers in soft- and hard-filled gelatin capsules, using excipients such as lactose or milk sugar and high molecular weight polyethylene glycols.

[0093] Tablets may be made by compression or molding, optionally with one or more accessory ingredients. Compressed tablets may be prepared using binders (e.g., gelatin or hydroxypropylmethylcellulose), lubricants, inert diluents, preservatives, disintegrants (e.g., sodium starch glycolate or cross-linked sodium carboxymethylcellulose), surfactants, or dispersing agents. Molded tablets may be made by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent.

[0094] Tablets and other solid dosage forms of pharmaceutical compositions (e.g., dragees, capsules (such as sprinkle capsules and gelatin capsules), pills, and granules) can optionally be scored or prepared with coatings and shells, such as enteric coatings and other coatings well known in the pharmaceutical formulation art. They can also be formulated to provide sustained or controlled release of the active ingredient therein, for example, using hydroxypropylmethylcellulose, other polymer matrices, liposomes, and / or microspheres in various proportions to achieve the desired release profile. They can be sterilized, for example, by filtration through a bacteria-retaining filter or by incorporating a sterilizing agent in the form of a sterile solid composition that can be dissolved in sterile water or other sterile injectable medium immediately before use. These compositions can optionally contain opacifying agents and can be composed to release the active ingredient(s) only, or preferentially, in a certain portion of the gastrointestinal tract, optionally in a delayed manner. Examples of implantable compositions that can be used include polymeric substances and waxes. The active ingredient can also be in microencapsulated form, if appropriate, with one or more of the above-mentioned excipients.

[0095] The liquid dosage form useful for oral administration includes pharmaceutically acceptable emulsion, lyophilized product for reconstitution, microemulsion, solution, suspension, syrup and elixir.In addition to active ingredient, liquid dosage form can contain the inert diluent commonly used in the art, such as water or other solvent, cyclodextrin and its derivatives, solubilizer and emulsifier, for example, ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, oil (especially cottonseed oil, peanut oil, corn oil, germ oil, olive oil, castor oil and sesame oil), glycerol, tetrahydrofuryl alcohol, polyethylene glycol and fatty acid ester of sorbitan, and their mixtures.

[0096] Besides inert diluents, the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, coloring, perfuming and preservative agents.

[0097] Suspensions may contain, in addition to the active compound, suspending agents such as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar, and tragacanth, and mixtures thereof.

[0098] Pharmaceutical compositions for rectal, vaginal, or urethral administration may be presented as suppositories, which can be prepared by mixing one or more active compounds with one or more suitable non-irritating excipients or carriers, including, for example, cocoa butter, polyethylene glycol, a suppository wax, or salicylates, and which are solid at room temperature but liquid at body temperature, so that they melt in the rectum or vaginal cavity and release the active compound.

[0099] Formulations of the pharmaceutical composition for oral administration may be presented as a mouthwash, oral spray, or oral ointment.

[0100] Alternatively, or additionally, the compositions may be formulated for delivery via a catheter, stent, wire, or other intraluminal device, which may be particularly useful for delivery to the bladder, urethra, ureter, rectum, or intestine.

[0101] Formulations which are suitable for vaginal administration also include pessaries, tampons, creams, gels, pastes, foams or spray formulations containing such carriers as are known in the art to be appropriate.

[0102] Dosage forms for topical or transdermal administration include powders, sprays, ointments, pastes, creams, lotions, gels, solutions, patches, and inhalants. The active compound may be mixed under sterile conditions with a pharmaceutically acceptable carrier, and any preservatives, buffers, or propellants that may be required.

[0103] The ointments, pastes, creams, and gels may contain, in addition to the active compound, excipients such as animal and vegetable fats, oils, waxes, paraffin, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonite, silicic acid, talc, zinc oxide, or mixtures thereof.

[0104] Powders and sprays can contain, in addition to the active compound, excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates and polyamide powder, or mixtures of these substances. Sprays can additionally contain customary propellants, such as chlorofluorohydrocarbons, and volatile unsubstituted hydrocarbons, such as butane and propane.

[0105] Transdermal patches have the additional advantage of providing controlled delivery of the compound of the present disclosure to the body.These dosage forms can be prepared by dissolving or dispersing the active compound in a suitable medium.Absorption enhancers can also be used to increase the flux of the compound across the skin.The rate of this flux can be controlled by providing a rate-controlling membrane or dispersing the compound in a polymer matrix or gel.

[0106] Ophthalmic preparations, eye ointments, powders, solutions, etc. are also considered to be within the scope of the present disclosure.Exemplary ophthalmic preparations are described in U.S. Publication Nos. 2005 / 0080056, 2005 / 0059744, 2005 / 0031697, and 2005 / 004074, and U.S. Patent No. 6,583,124, the contents of which are incorporated herein by reference in their entirety.If desired, liquid ophthalmic preparations have properties similar to those of tears, aqueous humor, or vitreous humor, or are compatible with these fluids.Preferred administration route is topical administration (for example, topical administration such as eye drops, or administration via implant).

[0107] Suppositories are also considered to be within the scope of the present disclosure.

[0108] As used herein, the phrases "parenteral administration" and "administered parenterally" refer to modes of administration other than enteral and topical administration, usually by injection, and include, but are not limited to, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal and intrasternal injection and infusion.

[0109] Pharmaceutical compositions suitable for parenteral administration comprise one or more active compounds in combination with one or more pharmaceutically acceptable sterile isotonic aqueous or non-aqueous solutions, dispersions, suspensions or emulsions, or sterile powders that can be reconstituted into sterile injectable solutions or dispersions immediately before use, which may contain antioxidants, buffers, bacteriostats, solutes that render the formulation isotonic with the blood of the intended recipient or suspending or thickening agents, or suspending or thickening agents.

[0110] Examples of suitable aqueous and non-aqueous carriers that can be used in the pharmaceutical compositions of the present disclosure include water, ethanol, polyols (glycerol, propylene glycol, polyethylene glycol, etc.), and suitable mixtures thereof, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate. Proper fluidity can be maintained, for example, by the use of coating materials such as lecithin, by maintaining the required particle size in the case of dispersions, and by the use of surfactants.

[0111] These compositions may also contain auxiliary agents such as preservatives, wetting agents, emulsifying agents, and dispersing agents. Prevention of microbial action can be ensured by including various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, etc. It may also be desirable to include isotonic agents such as sugars and sodium chloride in the composition. Furthermore, prolonged absorption of injectable pharmaceutical forms can be achieved by including agents that delay absorption, such as aluminum monostearate and gelatin.

[0112] In some cases, it is desirable to slow down the absorption of drugs from subcutaneous or intramuscular injection in order to prolong the effect of drugs.This can be achieved by using a liquid suspension of crystalline or amorphous materials with low water solubility.The absorption rate of drugs depends on their dissolution rate, which in turn depends on crystal size and crystalline form.Alternatively, delayed absorption of parenterally administered drug forms can be achieved by dissolving or suspending drugs in oil vehicles.

[0113] Injectable depot forms are made by forming microencapsulated matrices of the subject compounds in biodegradable polymers such as polylactide-polyglycolide. The rate of drug release can be controlled depending on the ratio of drug to polymer and the nature of the particular polymer used. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Depot injectable formulations can also be prepared by entrapping the drug in liposomes or microemulsions that are compatible with body tissues.

[0114] For use in the methods of the present disclosure, the active compound can be provided per se or as a pharmaceutical composition containing 0.1 to 99.5% (more preferably 0.5 to 90%) of the active ingredient in combination with, for example, a pharmaceutically acceptable carrier.

[0115] The introduction method may be carried out by a rechargeable device or a biodegradable device. In recent years, various sustained-release polymeric devices have been developed and tested in vivo for the controlled delivery of drugs such as proteinaceous biopharmaceuticals. Various biocompatible polymers (such as hydrogels), including both biodegradable and non-degradable polymers, can be used to form implants for sustained release of compounds at specific target sites.

[0116] Actual dosage levels of the active ingredient in the pharmaceutical compositions may be varied to obtain an amount of the active ingredient that is effective to obtain the desired therapeutic response for a particular patient, composition, and mode of administration without being toxic to the patient.

[0117] The selected dosage level will depend on a variety of factors, including the activity of the particular compound or combination of compounds, or esters, salts, or amides thereof, used, the route of administration, the time of administration, the rate of excretion of the particular compound(s) being used, the duration of treatment, other drugs, compounds, and / or materials used in combination with the particular compound(s) being used, the age, sex, weight, condition, general health, and previous medical history of the patient being treated, and similar factors well known in the medical arts.

[0118] A physician or veterinarian skilled in the art can easily determine and prescribe the therapeutically effective amount of the pharmaceutical composition required. For example, the physician or veterinarian can start the dosage of the pharmaceutical composition or compound at a level lower than that required to achieve the desired therapeutic effect, and gradually increase the dosage until the desired effect is achieved. A "therapeutically effective amount" refers to the concentration of the compound sufficient to elicit the desired therapeutic effect. It is generally understood that the effective amount of a compound will vary depending on the subject's weight, sex, age, and medical history. Other factors that affect the effective amount include, but are not limited to, the severity of the patient's condition, the disorder being treated, the stability of the compound, and, if desired, other types of therapeutic agents administered together with the anhydrous crystalline form of the compound of Formula (I) of the present disclosure. A larger total dose can be delivered by administering the agent multiple times. Methods for determining efficacy and dosage are known to those skilled in the art (Isselbacher et al., (1996) Harrison's Principles of Internal Medicine, 13th Edition, 1814-1882 (incorporated herein by reference)).

[0119] Generally, a suitable daily dose of an active compound used in the compositions and methods of the present disclosure will be that amount of the compound that is the lowest dose effective to produce a therapeutic effect. Such an effective dose will generally depend upon the factors described above.

[0120] If desired, the effective daily dose of the active compound can be administered as 1, 2, 3, 4, 5, 6 or more subdoses administered separately at appropriate intervals throughout the day, optionally in unit dosage form.In some embodiments of the present disclosure, the active compound can be administered two or three times a day.In a preferred embodiment, the active compound is administered once a day.

[0121] Patients receiving this treatment may be any animal in need, including primates, particularly humans, as well as other mammals such as horses, cattle, pigs, and sheep, as well as poultry and pets in general.

[0122] Wetting agents, emulsifying agents and lubricating agents such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, releasing agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants can also be present in the composition.

[0123] Examples of pharmaceutically acceptable antioxidants include: (1) water-soluble antioxidants such as ascorbic acid, cysteine ​​hydrochloride, sodium bisulfate, sodium metabisulfite, and sodium sulfite; (2) oil-soluble antioxidants such as ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), lecithin, propyl gallate, and α-tocopherol; and (3) metal chelating agents such as citric acid, ethylenediaminetetraacetic acid (EDTA), sorbitol, tartaric acid, and phosphoric acid.

[0124] Having generally described the invention, the same will be more readily understood by reference to the following examples, which are included solely for the purpose of illustrating certain aspects and embodiments of the invention and are not intended to limit the invention. Example Analysis method X-ray powder diffraction

[0125] X-ray powder diffraction (XRPD) patterns were collected on an Empyrean diffractometer or X'Pert3 diffractometer using CuKα radiation (45 kV, 40 mA) or a PANalytical Empyrean diffractometer.

[0126] Details of data collection are summarized in Table 2. [Table 2] HPLC

[0127] Purity analyses were performed on an Agilent HP1100 series system equipped with a diode array detector using ChemStation software vB.04.03 using the methods detailed in Table 3 below. [Table 3] Thermogravimetry and differential scanning calorimetry

[0128] Thermogravimetric analysis (TGA) data was collected using a TA Q500 / Q5000 TGA (TA Instruments). Differential scanning calorimetry (DSC) was performed using a TA Q200 / Q2000 DSC (TA Instruments). The method parameters are shown in Table 4 below. [Table 4] Example 1: Synthesis of Form A by crystallization from an isopropanol / water mixture

[0129] Formula (I) (1.00 g) was weighed into a glass vial, deionized water (10 mL) was added, and after stirring at 35° C., a clear solution was obtained. Isopropanol (2 mL) was added, followed by Form A seed crystals of Formula (I). 18 mL isopropanol was added over 8 hours at 35° C. and held for 1 hour. The mixture was cooled to 25° C. over 2 hours and held at 25° C. for approximately 1 hour. The white solid present was then isolated by filtration, and XRPD analysis showed it to be anhydrous Form A of Formula (I) ( FIG. 1 ). The solid was then dried under vacuum at 40° C. for approximately 20 hours (yield not determined). Example 2: Synthesis of Form A by crystallization from an ethanol / water mixture A. 5 wt% seed crystals, 8 hours of EtOH

[0130] Formula (I) (1.02 g) was placed in a 100 mL reactor with deionized water (10 mL). The mixture was stirred at 35 °C using an overhead stirrer (approximately 300 rpm, approximately 40 m / min) to obtain a clear solution. 2 mL of EtOH was added to the solution, followed by 1-2 mg of seed crystals (Formula (I) Form A). The seed crystal formation point occurred when the EtOH / HO ratio was 1:5 v / v. The seed crystals had an Mv of 34.2 μm with partially agglomerated crystals, and the dried, ground seed crystals had a D50 of 14.9 μm. A cloudy suspension was observed. An additional 50.0 mg of seed crystals (Formula (I) Form A) was added, and the mixture was held at 35 °C without stirring for approximately 10 minutes. The resulting slurry was stirred at 35 °C for approximately 8 hours, and 18 mL of EtOH was slowly added. The mixture was then held at 35 °C without stirring for approximately 1 hour. The mixture was cooled to 20°C over 1 hour and maintained at that temperature without stirring for approximately 1 hour. The white solid present was then isolated by filtration and washed with 2 x 10 mL EtOH. The cake was dried under vacuum at 40°C for 20 hours to give 0.86 g of a solid (solid yield approximately 86%). XRPD analysis showed that the solid was anhydrous crystalline Form A of Formula (I) (Figure 1). and Figure 2 "8h, 5% by weight of seeds, EtOH" ). B. 5 wt% seed crystals, 4 hours of EtOH

[0131] Following the procedure outlined in Example 2A, 1.00 g of Formula (I) in 10 mL of water, an additional 50.1 mg of seed crystals (Form A of Formula (I)), and 18 mL of EtOH were slowly added over 4 hours to yield 0.85 g of solid (approximately 85% solid yield). XRPD analysis indicated the solid was anhydrous crystalline Form A of Formula (I) (Figure 2). "4h, 5% by weight of seeds, EtOH" ). C. 1 wt% seed crystals, 4 hours of EtOH

[0132] Following the procedure outlined in Example 2A, 1.03 g of Formula (I) in 10 mL of water, an additional 10.6 mg of seed crystals (Form A of Formula (I)), and 18 mL of EtOH were slowly added over 4 hours to yield 0.87 g of solid (approximately 87% solid yield). XRPD analysis indicated the solid was anhydrous crystalline Form A of Formula (I) (Figure 2). "4h, 1% by weight of seeds, EtOH" ). D. 5 wt% seed crystals, EtOH for 4 hours / H 2 O addition

[0133] Formula (I) (1.01 g) was placed in a 100 mL reactor with deionized water (8 mL). The mixture was stirred at 35 °C using an overhead stirrer (approximately 450 rpm, approximately 60 m / min) to obtain a clear solution. 1 mL of EtOH was added to the solution, followed by 1-2 mg of seed crystals (Formula (I) Form A). The seed crystal formation point occurred when the EtOH / HO ratio was 1:8 v / v. The seed crystals had an Mv of 34.2 μm with partially agglomerated crystals, and the dried, ground seed crystals had a D50 of 14.9 μm. A cloudy suspension was observed. An additional 50.6 mg of seed crystals (Formula (I) Form A) was added, and the mixture was held at 35 °C for approximately 20 minutes without stirring. The resulting slurry was stirred at 35 °C for approximately 4 hours while 21 mL of EtOH / HO (19:1 v / v) was slowly added. The mixture was then held at 35°C without stirring for about 1 hour. The mixture was cooled to 20°C over 1 hour and held at that temperature without stirring for about 1 hour. The white solid present was then isolated by filtration and washed with 2x10 mL EtOH. The cake was dried under vacuum at 40°C for 7 hours to give 0.87 g of a solid (solid yield about 87%). XRPD analysis showed that the solid was anhydrous crystalline Form A of Formula (I) (Figure 2). "4h, 5% by weight of seeds, EtOH / H 2 O」 ). E. Crushed seed crystals

[0134] A 100 mL V-type reactor was charged with Form A of Formula (I) (1.2 g) and maintained at 10°C with magnetic stirring using a cross stirrer throughout the procedure. 20 mL of EtOH was charged to the reactor equipped with a sonication probe. The mixture was sonicated for approximately 100 minutes. The white solid present was then isolated by filtration and washed with 2 x 10 mL EtOH. The cake was dried under vacuum at room temperature for 10 hours.

[0135] All experiments yielded rod-shaped crystalline aggregates (Form A of Formula (I)), with Mv ranging from 76.2 to 97.6 μm and loose densities of 0.13 to 0.16 g / mL (tapped density: 0.19 to 0.30 g / mL). No significant differences in morphology, particle size distribution (PSD), and loose densities were observed among these three experiments (Examples 2A to 2C). The morphology and particle size of the product were consistent before and after drying. Without wishing to be bound by any particular theory, the aggregates may be caused by high local supersaturation at the entry point of the antisolvent. Another experiment was conducted using EtOH / HO (19:2, v / v) as the antisolvent to reduce local supersaturation (Example 2D). Compared to the experiment using EtOH as the antisolvent, the aggregation was alleviated. The resulting crystals had an Mv of 63.1 μm and a loose density of 0.16 g / mL. The tap density increased to 0.38 g / mL. Using polarized light microscopy, rod-shaped crystals were observed in the EtOH / water system for both the wet and dry cakes (Figures 3A-6B).

[0136] The particle size distribution of anhydrous crystalline Form A of Formula (I) under various crystallization conditions is summarized in Table 5. The particle size is consistent before drying and before and after drying by sonicating the sample at 30 W for 30 seconds. There is a difference in particle size before and after sonication (e.g., before 4C drying and after 4C drying). [Table 5] F. Seed crystal, EtOH addition

[0137] Formula (I) (1.02 g) was weighed into a glass vial, deionized water (10 mL) was added, and after stirring at 35° C., a clear solution was obtained. EtOH (2 mL) was added, followed by Form A crystals of Formula (I). 18 mL of EtOH was added at 35° C. and held for 1 hour. Cooled to 20° C. and held at 20° C. for approximately 1 hour. The white solid present was then isolated by filtration, and XRPD analysis showed it to be anhydrous Form A of Formula (I). The solid was then dried under vacuum at room temperature for approximately 22 hours (0.86 g, approximately 80% recovery). G. Seed crystal, 19:2EtOH / H2O addition

[0138] Formula (I) (1.01 g) was weighed into a glass vial, and deionized water (8 mL) was added. After stirring at 35° C., a clear solution was obtained. EtOH (1 mL) was added, followed by Form A crystals of Formula (I). The mixture was charged with 21 mL of EtOH / HO (19:2, v / v) and held for approximately 1 hour. It was cooled to 20° C. and held at 20° C. for approximately 1 hour. The white solid present was then isolated by filtration, and XRPD analysis showed it to be anhydrous Form A of Formula (I). The solid was then dried under vacuum at 40° C. for approximately 7 hours (0.87 g, 82% recovery). H. Seed crystal, 5:1 EtOH / H2O addition

[0139] Formula (I) (1.01 g) was weighed into a glass vial, and deionized water (8 mL) was added. After stirring at 35° C., a clear solution was obtained. EtOH (1 mL) was added, followed by Form A crystals of Formula (I). The mixture was charged with 30 mL of EtOH / HO (5:1, v / v) and held for approximately 1 hour. It was cooled to 20° C. and held at 20° C. for approximately 1 hour. The white solid present was then isolated by filtration, and XRPD analysis showed it to be anhydrous Form A of Formula (I). The solid was then dried under vacuum at 40° C. for approximately 6 hours (0.84 g, 80% recovery). I. 5 wt% seed crystals, 8 hours of EtOH

[0140] Formula (I) (1.02 g) was weighed and placed in a 100 mL reactor containing 10 mL of deionized water. After stirring for 10 minutes to obtain a clear solution, 2 mL of EtOH solvent was added, followed by 1-2 mg of Formula (I) Form A seeds. A cloudy or hazy appearance was observed. The solution was continued to stir for 10 minutes, after which approximately 50 mg of Formula (I) Form A seeds were added. The solution was then stirred for approximately 20 minutes. Next, 18 mL of EtOH solvent was added via a syringe pump over 8 hours at 35°C. The cloudy solution was then maintained at 35°C for 1 hour. Finally, the cloudy solution was cooled to 20°C over 1 hour and maintained at 20°C for approximately 11 hours. Example 3: Synthesis of Form A by Slurry A. 1:9 EtOH / H2O

[0141] Formula (I) (340.8 mg) was weighed into a glass vial. 1 mL of solvent (water / EtOH=9 / 1, v / v) was added. The resulting slurry was stirred at 50° C. for about 15 hours. The wet solid present was then isolated by centrifugation, which was shown by XRPD analysis to be Formula (I) Anhydrous Form A (yield not determined). B. 2:1 EtOH / H2O

[0142] Formula (I) (29.4 mg) was weighed into a glass vial. 1 mL of solvent (water / EtOH = 1 / 2, v / v) was added. The resulting slurry was stirred at 50°C for about 15 hours. The wet solid present was then isolated by centrifugation, which was shown by XRPD analysis to be Formula (I) Anhydrous Form A (yield was not determined). C. 1:9 IPA / H2O

[0143] Formula (I) (327.3 mg) was weighed into a glass vial. 1 mL of solvent (water / isopropanol = 9 / 1, v / v) was added. The resulting slurry was stirred at 50 °C for about 15 hours. The wet solid present was then isolated by centrifugation, which was shown by XRPD analysis to be Formula (I) Anhydrous Form A (yield was not determined). D. 2:1 IPA / H2O

[0144] Formula (I) (29.8 mg) was weighed into a glass vial. 1 mL of solvent (water / isopropanol = 1 / 2, v / v) was added. The resulting slurry was stirred at 50 °C for about 15 hours. The resulting white solid was then isolated by centrifugation, which was shown by XRPD analysis to be Formula (I) Anhydrous Form A (yield was not determined). Example 4: Thermogravimetric analysis and differential scanning calorimetry of formula (I)

[0145] Thermogravimetric analysis (TGA) of anhydrous Form A of Formula (I) showed a weight loss of 0.5% up to 150°C, consistent with the anhydrous form. Differential scanning calorimetry (DSC) showed a melting / decomposition endotherm at 203.5°C (onset temperature) (Figure 7).

[0146] Approximately 40 mg samples of Form A of Formula (I) were maintained at each corresponding condition for one month without significant change. A shoulder peak was observed in the DSC curves of the initial sample and samples after one or three months of storage at 25°C / 60% relative humidity (RH) and 40°C / 75% RH. No significant effect of the shoulder peak on shape or HPLC purity was observed. See Table 6. [Table 6] Example 5: Stability and forced decomposition testing of anhydrous crystals of formula (I) solid state stability

[0147] Samples of anhydrous crystalline Form A of Formula (I) were stored as solids at 25°C / 60% RH, 30°C / approximately 56%, and 40°C / 75% RH for the following periods: Samples were prepared in duplicate with a two-week offset. Each replicate was stored in a different container.

[0148] The anhydrous crystalline Form A of Formula (I) remained unchanged in terms of solid and particulate morphology after 1 and 3 months of storage at 25°C / 60% RH, 40°C / 75% RH, and 60°C. See Figure 8 after 3 months. The chemical purity of approximately 40 mg of the solid sample was also evaluated, and no significant degradation was observed after 1 month of storage. See Table 7. [Table 7] Stability of the solution

[0149] Samples of the anhydrous crystalline form A of formula (I) were mixed with acetonitrile, tetrahydrofuran, isopropyl alcohol, or an aqueous solution of ethanol Use it to prepare 100ml of ... and stored. The sample concentration was about 10 mg / mL, and stirring was continued.

[0150] At room temperature, a decrease in chemical purity from about 99.6% (at the 0-hour point) to about 99.1% - 99.2% (at the 24-hour point) was observed. The main growth impurity observed by HPLC eluted at RRT 0.72 (about 0.36% - about 0.40% at the 24-hour point) (see Table 8). [Table 8]

[0151] At 35 °C, a decrease in chemical purity from about 99.6% (at the 0-hour point) to about 98.2% - 98.4% (at the 24-hour point) was observed. The main growth impurity observed by HPLC eluted at RRT 0.72 (about 1.10% - about 1.32% at the 24-hour point) (see Table 9). [Table 9] Example 6: Determination of the solubility of anhydrous crystals of formula (I)

[0152] The anhydrous form A of formula (I) showed good solubility in simulated gastric fluid (SGF) exceeding 114.0 mg / mL at room temperature. In aqueous solutions adjusted to pH with NaOH and HCl solutions at room temperature, the solubility of form A of formula (I) was between 87.5 < S < 116.7 at pH 7.08 and 83.5 < S < 111.3 mg / mL at pH 9.14. The pH values of the aqueous solutions after the solubility tests were 5.13 and 5.15, respectively.

[0153] The equilibrium solubility of anhydrous Form A of Formula (I) was measured in water at 20° C. and 30° C. All samples were equilibrated at temperature for 6 hours, and the solubility of the supernatant was measured by HPLC and the solids were confirmed by XRPD (see Table 10). [Table 10]

[0154] No change in form was observed during the solubility test of Form A (Figure 9). Example 7: Dynamic Vapor Sorption of Anhydrous Crystals of Formula (I)

[0155] Dynamic vapor sorption (DVS) results showed that the mass of Form A of Formula (I) increased continuously with increasing humidity (Figure 10). Anhydrous Form A also showed a mass change of approximately 0.66% up to 80% RH, indicating that the sample was slightly hygroscopic. No change in morphology was observed during the DVS test (Figure 11). Example 8: Single crystal structure determination Form A

[0156] Form A was crystallized from an ethanol / water mixture as described in Example 2I. The crystals were rod-like in shape (FIG. 3A). Single-crystal X-ray diffraction data were collected at 296 K using a Bruker® D8 VENTURE diffractometer (Mo / Kα radiation; λ=0.71073 Å). Structural information and refinement parameters are shown in Table 11. [Table 11]

[0157] Single crystal structure analysis confirmed that crystalline Form A of Formula (I) is an anhydrate with an asymmetric unit consisting of one molecule of Formula (I) (Figure 12A). The bond lengths of C-O / C=O from the carboxyl groups were similar (C-O / C=O: 1.256 Å / 1.241 Å). Three residual electron density peaks (0.35, 0.31, and 0.25 e.Å) were assigned to hydrogen atoms around the N1 atom at distances of 1.031 Å, 0.887 Å, and 0.940 Å, respectively. -3) was observed. This suggests that the molecule of formula (I) was a zwitterion in the anhydrous form A crystals (Figures 12B and 12C). In the anhydrous crystalline form A, adjacent molecules of the compound of formula (I) are bonded to each other to form a three-dimensional packing structure via hydrogen bonds (OH··O, NH··O).

[0158] The absolute configuration of the Formula (I) molecule could not be determined from the diffraction data due to the weak anomalous scattering behavior of the Formula (I) molecule. The experimental XRPD is compared to the calculated XRPD pattern based on the single crystal structure, which shows consistent peaks (Figure 13). Incorporation by Reference

[0159] All publications and patents mentioned herein are incorporated by reference in their entirety as if each individual publication or patent was specifically and individually indicated to be incorporated by reference. In case of conflict, the present application, including definitions herein, will control. equivalent

[0160] While specific embodiments of the invention have been discussed, the above specification is illustrative and not limiting. Many variations of the invention will become apparent to those skilled in the art upon review of this specification and the following claims. The full scope of the invention should be determined by reference to the claims, along with their full scope of equivalents, and the specification together with such variations. The present invention includes the following embodiments. (Embodiment 1) An anhydrous crystalline compound having the structure of formula (I) [ka] (Embodiment 2) 2. The anhydrous crystalline compound of embodiment 1, wherein the 2θ values ​​are 18.8±0.2, 20.5±0.2, 26.4±0.2, 27.5±0.2, and 32.0±0.2. (Embodiment 3) 3. The anhydrous crystalline compound of embodiment 2 having 2θ values ​​of 18.8±0.2, 20.5±0.2, 26.1±0.2, 26.4±0.2, 27.5±0.2, 30.6±0.2, and 32.0±0.2. (Embodiment 4) 4. The anhydrous crystalline compound of embodiment 3 having 2θ values ​​of 15.8±0.2, 16.5±0.2, 18.8±0.2, 20.5±0.2, 25.5±0.2, 26.1±0.2, 26.4±0.2, 27.5±0.2, 30.6±0.2, and 32.0±0.2. (Embodiment 5) 7. The anhydrous crystalline compound of embodiment 6 having 2θ values ​​of 15.8±0.2, 16.5±0.2, 18.8±0.2, 20.5±0.2, 21.8±0.2, 22.3±0.2, 24.2±0.2, 25.5±0.2, 26.1±0.2, 26.4±0.2, 27.5±0.2, 30.4±0.2, 30.6±0.2, and 32.0±0.2. (Embodiment 6) 6. The anhydrous crystalline compound of embodiment 5, having an XRD pattern substantially as shown in FIG. 3. (Embodiment 7) A pharmaceutical composition comprising the anhydrous crystalline compound of any one of embodiments 1 to 6 and one or more pharmaceutically acceptable excipients. (Embodiment 8) 1. A process for preparing an anhydrous crystalline compound having the structure of formula (I), comprising:

change

Claims

1. Anhydrous crystals having the structure of formula (I) and having 2θ values ​​of 18.8±0.2, 20.5±0.2, 26.4±0.2, 27.5±0.2, and 32.0±0.

2. 【Chemistry 1】

2. 2. The anhydrous crystals of claim 1 having 2θ values ​​of 18.8±0.2, 20.5±0.2, 26.1±0.2, 26.4±0.2, 27.5±0.2, 30.6±0.2, and 32.0±0.

2.

3. 3. The anhydrous crystals of claim 1 or 2, having 2θ values ​​of 15.8±0.2, 16.5±0.2, 18.8±0.2, 20.5±0.2, 25.5±0.2, 26.1±0.2, 26.4±0.2, 27.5±0.2, 30.6±0.2, and 32.0±0.

2.

4. The anhydrous crystals of any one of claims 1 to 3, having 2θ values ​​of 15.8±0.2, 16.5±0.2, 18.8±0.2, 20.5±0.2, 21.8±0.2, 22.3±0.2, 24.2±0.2, 25.5±0.2, 26.1±0.2, 26.4±0.2, 27.5±0.2, 30.4±0.2, 30.6±0.2, and 32.0±0.

2.

5. 5. The anhydrous crystals of any one of claims 1 to 4, having 2θ values ​​of 10.2±0.2, 15.2±0.2, 15.8±0.2, 16.5±0.2, 17.6±0.2, 18.1±0.2, 18.8±0.2, 20.5±0.2, 21.8±0.2, 22.3±0.2, 22.9±0.2, 24.2±0.2, 25.4±0.2, 26.1±0.2, and 26.4±0.

2.

6. 2θ values: 10.2±0.2, 15.2±0.2, 15.8±0.2, 16.5±0.2, 17.6±0.2, 18.1±0.2, 18.8±0.2, 20.5±0.2, 21.8±0.2, 22.3±0.2, 22.9±0.2, 24.2±0.2, 25.4±0.2, 26.1±0.2, 26.4±0.2, 27.5±0.2, 28.1±0.2 6. The anhydrous crystals of any one of claims 1 to 5, having α, β-blockers (α, β-blockers) of 28.8±0.2, 29.3±0.2, 30.4±0.2, 30.6±0.2, 32.0±0.2, 33.4±0.2, 33.6±0.2, 34.6±0.2, 35.8±0.2, 36.7±0.2, 37.3±0.2, 38.2±0.2, 38.6±0.2, and 39.2±0.

2.

7. A pharmaceutical composition comprising the anhydrous crystals of any one of claims 1 to 6 and one or more pharmaceutically acceptable excipients.

Images